GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GNI Group Ltd (FRA:3G6) » Definitions » Cyclically Adjusted Revenue per Share

GNI Group (FRA:3G6) Cyclically Adjusted Revenue per Share : €1.18 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is GNI Group Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GNI Group's adjusted revenue per share for the three months ended in Mar. 2024 was €0.703. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.18 for the trailing ten years ended in Mar. 2024.

During the past 12 months, GNI Group's average Cyclically Adjusted Revenue Growth Rate was 41.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 41.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 43.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GNI Group was 45.40% per year. The lowest was 41.30% per year. And the median was 41.40% per year.

As of today (2024-05-27), GNI Group's current stock price is €12.00. GNI Group's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €1.18. GNI Group's Cyclically Adjusted PS Ratio of today is 10.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GNI Group was 81.59. The lowest was 7.08. And the median was 25.42.


GNI Group Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for GNI Group's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GNI Group Cyclically Adjusted Revenue per Share Chart

GNI Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.52 0.71 0.92 1.19

GNI Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 1.02 1.11 1.19 1.18

Competitive Comparison of GNI Group's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, GNI Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GNI Group's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GNI Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GNI Group's Cyclically Adjusted PS Ratio falls into.



GNI Group Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GNI Group's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.703/107.2000*107.2000
=0.703

Current CPI (Mar. 2024) = 107.2000.

GNI Group Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.020 98.000 0.022
201409 0.027 98.500 0.029
201412 0.040 97.900 0.044
201503 0.052 97.900 0.057
201506 0.053 98.400 0.058
201509 0.052 98.500 0.057
201512 0.061 98.100 0.067
201603 0.072 97.900 0.079
201606 0.058 98.100 0.063
201609 0.073 98.000 0.080
201612 0.114 98.400 0.124
201703 0.085 98.100 0.093
201706 0.082 98.500 0.089
201709 0.142 98.800 0.154
201712 0.219 99.400 0.236
201803 0.191 99.200 0.206
201806 0.217 99.200 0.235
201809 0.275 99.900 0.295
201812 0.264 99.700 0.284
201903 0.299 99.700 0.321
201906 0.361 99.800 0.388
201909 0.368 100.100 0.394
201912 0.386 100.500 0.412
202003 0.400 100.300 0.428
202006 0.418 99.900 0.449
202009 0.459 99.900 0.493
202012 0.495 99.300 0.534
202103 0.631 99.900 0.677
202106 0.407 99.500 0.438
202109 0.491 100.100 0.526
202112 0.504 100.100 0.540
202203 0.631 101.100 0.669
202206 0.626 101.800 0.659
202209 0.673 103.100 0.700
202212 0.679 104.100 0.699
202303 0.617 104.400 0.634
202306 1.356 105.200 1.382
202309 0.836 106.200 0.844
202312 0.674 106.800 0.677
202403 0.703 107.200 0.703

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


GNI Group  (FRA:3G6) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GNI Group's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.00/1.18
=10.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GNI Group was 81.59. The lowest was 7.08. And the median was 25.42.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GNI Group Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of GNI Group's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GNI Group (FRA:3G6) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GNI Group Ltd (FRA:3G6) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
Shinjuku Park Tower, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-1030
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.

GNI Group (FRA:3G6) Headlines

No Headlines